ImageneBio, Inc.
Close on Oct 19, 2026
- Market cap
- $64.65M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 11, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 5, 2026 | Before market open | – | $-0.63 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 7, 2026 | During market hours | – | – | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 10, 2026 | Before market open | – | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 12, 2025 | Before market open | – | $-2.91 | – |
| Q4 FY2023 Ended Dec 31, 2023 | Jan 18, 2024 | During market hours | – | – | – |
| Q3 FY2023 Ended Sep 30, 2023 | Nov 9, 2023 | Before market open | $1.20M | – | – |
| Q2 FY2021 Ended Jun 30, 2021 | Aug 12, 2021 | Before market open | – | – | – |
| Q1 FY2021 Ended Mar 31, 2021 | May 13, 2021 | Before market open | – | – | – |
Press releases
Announcements ImageneBio filed with the SEC
ImageneBio Reports Second Quarter 2026 Financial Results
Results of operations · EX-99.1 to Form 8-K
ImageneBio Reports First Quarter 2026 Financial Results and Provides
Results of operations · EX-99.1 to Form 8-K
ImageneBio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Company Update
Results of operations · EX-99.1 to Form 8-K
ImageneBio Reports Third Quarter 2025 Financial Results and Provides
Results of operations · EX-99.1 to Form 8-K
I MAGENE B IO , I NC .
Executive or director change · Other events · EX-99.1 to Form 8-K
Disclaimer This presentation contains “forward-looking
Material agreement · Acquisition or disposition completed · Unregistered share sale · Executive or director change · Charter or bylaw amendment · Regulation FD disclosure · EX-99.1 to Form 8-K
UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION
Material agreement · Acquisition or disposition completed · Unregistered share sale · Executive or director change · Charter or bylaw amendment · Regulation FD disclosure · EX-99.2 to Form 8-K
Inmagene Biopharmaceuticals Announces Completion of Merger with Ikena Oncology and Concurrent Private
Regulation FD disclosure · EX-99.1 to Form 8-K
Ikena Oncology Announces Stockholder Approval of Merger with Inmagene Biopharmaceuticals
Executive or director change · Shareholder vote results · Other events · EX-99.1 to Form 8-K
Ikena Oncology Announces ISS and Glass Lewis Recommend Stockholders Vote FOR Proposed Merger
Other events · EX-99.1 to Form 8-K
Inmagene Doses First Patient in the ADAPTIVE Phase 2b Trial of IMG-007, a
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Inmagene Biopharmaceuticals Announce Agreement for Merger and Private Placement
Material agreement · Unregistered share sale · Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Disclaimer This presentation and the
Material agreement · Unregistered share sale · Executive or director change · Regulation FD disclosure · EX-99.2 to Form 8-K
Ikena Oncology Announces Strategic Update
Exit or restructuring costs · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Forward Looking Statement Any statements in presentation other than
Exit or restructuring costs · Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Ikena Oncology Appoints Caroline Germa, M.D. as Chief Medical Officer
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Ikena Oncology Outlines Key Priorities and Provides Corporate Updates
Results of operations · Exit or restructuring costs · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Ikena Oncology Shares Initial Positive and Differentiated Dose Escalation Data from IK-930 Phase I Trial and Reports Third Quarter 2023 Financial Results
Results of operations · Other events · EX-99.1 to Form 8-K
Ikena Oncology Acquires Pionyr Immunotherapeutics in All-Stock Transaction
Material agreement · Acquisition or disposition completed · Unregistered share sale · Charter or bylaw amendment · Regulation FD disclosure · EX-99.1 to Form 8-K
Ikena Oncology Reports First Quarter 2023 Financial Results and Highlights Advancements Across
Material agreement · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Developing Biology-Driven Medicines and Expanding the Impact of Targeted
Material agreement · Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Ikena Oncology Announces $40 Million Underwritten Offering
Material agreement · Regulation FD disclosure · Other events · EX-99.3 to Form 8-K
Ikena Oncology Shares Differentiation Profile of IK-930, a Novel
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Developing Biology-Driven Medicines and Expanding the Impact of Targeted
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K